RenovoRx (NASDAQ:RNXT) Stock: Insider Ramtin Agah Acquires 50,000 Shares

RenovoRx, Inc. (NASDAQ:RNXT – Get Free Report) CMO Ramtin Agah acquired 50,000 shares of the company’s stock in a transaction on Monday, November 16th. The shares were acquired at an average cost of $0.93 per share, for a total transaction of $46,500.00. Following the completion of the acquisition, the chief marketing officer owned 848,460 shares of the company’s stock, valued at approximately $789,067.80. The trade was a 6.26% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

RenovoRx Trading Down 8.2%

RNXT opened at $0.95 on Tuesday. The firm has a 50-day moving average price of $1.42 and a 200-day moving average price of $1.11. RenovoRx, Inc. has a twelve month low of $0.73 and a twelve month high of $2.59.

RenovoRx (NASDAQ:RNXT – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). RenovoRx had a negative net margin of 469.02% and a negative return on equity of 133.49%. The business had revenue of $1.07 million for the quarter, compared to analysts’ expectations of $1.06 million. Equities research analysts anticipate that RenovoRx, Inc. will post -0.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on RNXT shares. Weiss Ratings upgraded RenovoRx from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, September 2nd. Wall Street Zen downgraded RenovoRx from a “hold” rating to a “sell” rating in a research note on Monday, November 9th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, RenovoRx presently has a consensus rating of “Moderate Buy” and an average price target of $8.50.

Get Our Latest Stock Analysis on RNXT

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. State Street Corp boosted its stake in RenovoRx by 501.6% during the third quarter. State Street Corp now owns 314,636 shares of the company’s stock valued at $491,000 after buying an additional 262,332 shares during the period. T3 Companies LLC bought a new position in shares of RenovoRx in the third quarter worth approximately $151,000. Finally, Cetera Investment Advisers raised its stake in RenovoRx by 205.1% in the third quarter. Cetera Investment Advisers now owns 57,976 shares of the company’s stock valued at $90,000 after purchasing an additional 38,976 shares in the last quarter. 3.10% of the stock is currently owned by hedge funds and other institutional investors.

About RenovoRx

(Get Free Report)

RenovoRx, Inc. is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its approach is designed to deliver therapy directly to targeted tissue through the arteries that supply it, with the goal of limiting exposure to the rest of the body. The company’s platform includes RenovoCath, a catheter cleared by the U.S. Food and Drug Administration for the localized infusion of therapeutic agents. RenovoRx is also evaluating RenovoGem, a combination of its delivery approach and the chemotherapy drug gemcitabine, for patients with locally advanced pancreatic cancer.

Featured Articles

Insider Buying and Selling by Quarter for RenovoRx (NASDAQ:RNXT)

Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.